Program Description
Chronic inflammatory demyelinating polyneuropathy (CIPD) follows a progressive disabling course, and disease-related disability is common among patients. Current treatment goals focus on decreasing clinical burden, reducing symptoms, improving functional ability, and maintaining remission. Immunoglobulin (Ig) is often initiated as therapy for CIDP and can be administered via intravenous (IV) or subcutaneous (SC), though treatment choice should consider patient preference and adverse effects. Specialty pharmacists in particular must be able to interpret nuances in changing from IVIg to SCIg formulations for patients with CIPD as well as be aware of the monitoring and optimization of CIDP therapy. This activity will also explore considerations brought about by the COVID-19 pandemic influencing shared clinical decision making for treatment with immunoglobulin therapy.
Target Audience: Specialty pharmacists
Type of Activity: Application
Release date: October 26, 2021
Expiration date: October 26, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the current efficacy, safety, dosing, and administration of therapies for chronic inflammatory demyelinating polyneuropathy (CIDP)
- Analyze best practices for the formulation transition of intravenous to subcutaneous immunoglobulin (IVIg to SCIg) among patients with CIDP
- Identify the role of specialty pharmacists in monitoring therapy and optimizing the management of patients
Leslie Myers, RPh, PharmD, IgCP
Clinical Pharmacist
Specialty and Infusion Services
Optum Infusion Pharmacy
Raleigh, North Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-368-H01-P. The activity is available for CE credit through October 26, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Leslie Myers, RPh, PharmD, IgCP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle Carlson, PharmD; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms